Relmada Therapeutics (RLMD) Receivables (2022)

Relmada Therapeutics (RLMD) reported Receivables of $1.0 million for Q4 2022.

Relmada Therapeutics (RLMD) Receivables (2022) Analysis & Trends

Relmada Therapeutics (RLMD) has 1 years of Receivables data on file, last reported at $1.0 million in Q4 2022.

  • Receivables for Q4 2022 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $1.0 million (changed N/A YoY), and the FY2022 annual result was $1.0 million, changed N/A from the prior year.
  • Receivables held at $1.0 million in Q4 2022 per RLMD's latest filing.
  • Over five years, Receivables peaked at $1.0 million in Q4 2022 and troughed at $1.0 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 13.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 2.00 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Relmada Therapeutics 581.07 Mn 581.07 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 1.02 Mn